2026-2032 年干眼症治疗市场（依产品类型、通路和地区）

干眼症治疗市场评估 - 2026-2032

干眼症的盛行率不断上升，尤其是人口老化和萤幕使用者数量的增加，正在推动干眼症治疗市场的发展。根据 Verified Market Research 分析师预测，干眼症治疗市场规模将从 2024 年的约 88.1 亿美元下降到 2032 年的 227.1 亿美元。

干眼症治疗市场的快速扩张主要归因于全球对有效治疗方法的需求不断增加以及治疗方案的技术进步，预计这将推动市场在 2026 年至 2032 年期间以 13.86% 的复合年增长率增长。

干眼症治疗市场定义/概述

干眼症是一种以泪液分泌不足和泪液蒸发过快为特征的疾病，会导致不适和视力下降。干眼症的治疗方法包括人工泪液、抗发炎药物以及保留或刺激泪液分泌的手术。

此外，干眼症的治疗有广泛的应用，包括即时缓解症状、控制潜在原因和预防进一步的併发症。无防腐剂配方和新药物输送系统等治疗方法的改进正在改善患者的治疗效果，从而推动市场成长。

推动干眼症治疗市场成长的关键因素有哪些？

干眼症症状日益普遍，推动了市场发展。根据美国美国超过 1,600 万成年人被诊断出患有干眼症，另有数百万人可能尚未确诊。患者数量的增长催生了对更有效治疗方案的需求。

人口老化正在催生巨大的干眼症治疗需求。根据世界卫生组织 (WHO) 的数据，到 2030 年，全球六分之一的人口将超过 60 岁。由于干眼症在老年人群中更为普遍，人口老化预计将成为市场扩张的驱动力。

此外，萤幕使用时间的增加和数位眼睛疲劳也推动了对干眼症治疗的需求。根据视力委员会2020年发布的一项调查，59%的美国人因长时间使用萤幕而出现数位眼睛疲劳症状，这与干眼症直接相关。随着萤幕使用时间的增加，对有效治疗方法的需求也在成长。

影响干眼症治疗市场采用的主要挑战有哪些？

干眼症创新疗法的高昂成本是其广受接受的一大障碍。长期治疗需要昂贵的处方药、专业眼药水以及诸如泪小管塞和热脉衝系统等医疗设备。在医疗保险覆盖有限或自付费用较高的地区，患者面临巨大的治疗障碍，这导致他们推迟治疗或使用对控制病情无益的非处方药。

许多出现症状的人没有就医，因为他们误以为这只是暂时的不适或环境因素。此外，医疗保健提供者并不总是将干眼症视为重大健康问题，尤其是在早期阶段。缺乏认知和诊断阻碍了有效治疗的实施，因为患者不知道这种疾病是慢性的，也不知道有专门的治疗方法可以显着改善他们的生活品质。

此外，治疗结果​​的差异也对干眼症治疗方法的采用构成了挑战。由于干眼症的成因多种多样，包括环境因素、荷尔蒙变化和潜在疾病，因此不同患者的治疗结果差异很大。有些患者对某些治疗方法没有反应，而有些患者则会出现副作用，导致不愿意继续使用。这种治疗结果的不可预测性导致患者感到沮丧，降低了对联合治疗方法的依从性，并降低了旨在长期控制干眼症的先进治疗方法的整体采用率。

目录

第一章 全球干眼症治疗市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 全球干眼症治疗市场预测

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球干眼症治疗市场（依产品类型）

• 概述
• 人工泪液
• 抗发炎药物
• 穿刺塞
• 分泌者
• 其他的

6. 全球干眼症治疗市场（依通路划分）

• 概述
• 医院药房
• 零售药局
• 网路药局

7. 全球干眼症治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

第八章全球干眼症治疗市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• Novartis AG
• Allergan plc
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Akorn, Inc.
• Thea Pharmaceuticals Limited
• OASIS Medical

第十章 附录

• 相关调查

Dry Eye Syndrome Treatment Market Valuation - 2026-2032

The increasing prevalence of dry eye syndrome, particularly among the aging population and increased screen time users, is driving the Dry Eye Syndrome Treatment Market upwards. According to the analyst from Verified Market Research, the Dry Eye Syndrome Treatment Market is estimated to reach a valuation of USD 22.71 Billion in 2032, by subjugating around USD 8.81 Billion valued in 2024.

The rapid expansion of the Dry Eye Syndrome Treatment Market is primarily driven by the rising global demand for effective therapies, as well as technological advancements in treatment options. It enables the market to grow at a CAGR of 13.86% from 2026 to 2032.

Dry Eye Syndrome Treatment Market: Definition/ Overview

Dry eye syndrome is a condition characterized by insufficient tear production or rapid tear evaporation, leading to discomfort and potential vision problems. Treatment options for dry eye syndrome include artificial tears, anti-inflammatory medications, and procedures to conserve tears or stimulate tear production.

Furthermore, dry eye syndrome treatments have a wide range of applications, including providing immediate relief from symptoms, managing underlying causes, and preventing further complications. Improved treatments, such as preservative-free formulations and novel drug delivery systems, are enhancing patient outcomes and driving market growth.

What are the Key Drivers Propelling the Growth of the Dry Eye Syndrome Treatment Market?

Dry eye condition is becoming increasingly common, which is a major market driver. According to the National Eye Institute (NEI), more than 16 million adults in the United States have been diagnosed with DES, with millions more potentially undiagnosed. The growing patient population demands more effective treatment choices.

The aging population is greatly increasing the need for dry eye remedies. According to the World Health Organization (WHO, by 2030, one in every six persons worldwide would be 60 or older. Because dry eye conditions are more common among older persons, the aging population is likely to drive market expansion.

Furthermore, the increase in screen time and digital eye strain is driving demand for dry eye remedies. According to a Vision Council study published in 2020, 59% of American people express symptoms of digital eye strain because of prolonged screen use, which is directly linked to dry eye syndrome. As screen time increases, so does the demand for effective therapies.

What are the Key Challenges Impacting the Adoption of Dry Eye Syndrome Treatment in the Market?

The high expense of innovative treatments for dry eye syndrome is a major barrier to their acceptance. Long-term treatment requires expensive prescription medications, specialist eye drops, and medical devices such as punctual plugs or thermal pulsation systems. Patients in areas with limited healthcare coverage or high out-of-pocket charges face considerable barriers due to these prices. Patients delay therapy or use over-the-counter medicines, which are not beneficial for managing the illness.

Many individuals experiencing symptoms do not seek medical attention, mistaking their condition for temporary discomfort or attributing it to environmental factors. Furthermore, healthcare providers do not always prioritize dry eye syndrome as a significant health issue, especially in the early stages. This lack of awareness and diagnosis hinders the adoption of effective treatments, as patients do not realize the chronic nature of the condition or the availability of specialized therapies that could significantly improve their quality of life.

Furthermore, the variability in treatment effectiveness also poses a challenge in the adoption of dry eye syndrome treatments. Since dry eye syndrome has multiple causes, including environmental factors, hormonal changes, and underlying medical conditions, treatment outcomes vary greatly from one patient to another. Some patients do not respond well to certain therapies or experience side effects that discourage continued use. This unpredictability in treatment response led to patient frustration, reduced compliance with prescribed therapies, and lower overall adoption of advanced treatments designed to manage the condition long-term.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Artificial Tears?

According to VMR analysis, the artificial tears segment is estimated to dominate the market in the product type segment during the forecast period. Artificial tears provide immediate relief by lubricating the eyes and are widely available over the counter, making them highly accessible to patients. This widespread availability and ease of use contribute significantly to their market dominance.

Also, technological advancements have led to the development of preservative-free and long-lasting formulations of artificial tears. These innovations have enhanced the efficacy and safety profile of artificial tears, making them more appealing to both patients and healthcare providers. The improved formulations address concerns about preservative-related irritation and offer longer-lasting relief, further driving their popularity in the market.

Furthermore, artificial tears are often recommended as a first-line treatment for dry eye syndrome by eye care professionals. They are suitable for mild to moderate cases of dry eye and be used in conjunction with other treatments for more severe cases. This application's versatility contributes to their widespread use and market dominance.

What are the Potential Factors for the Growth of Retail Pharmacies in the Market?

The retail pharmacies segment is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. Retail pharmacies offer widespread accessibility and convenience for patients seeking over-the-counter dry eye treatments like artificial tears and lubricating eye drops. They are often the first point of contact for individuals looking for immediate relief from dry eye symptoms, contributing to their market dominance.

The growing number of chain pharmacies and drugstores has significantly expanded the reach of retail pharmacies. These establishments often offer a wide range of dry eye products, from basic artificial tears to more specialized treatments. The convenience of accessing these products alongside other healthcare needs makes retail pharmacies a preferred channel for many consumers.

Furthermore, many retail pharmacies now offer personalized in-store consultations with pharmacists. These consultations provide valuable guidance to customers in selecting appropriate dry eye treatments, enhancing the overall customer experience, and building trust. This personalized approach, combined with the immediate availability of products, strengthens the position of retail pharmacies in the Dry Eye Syndrome Treatment Market.

Country/Region-wise Acumens

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. North America, particularly the U.S., has a high prevalence of dry eye syndrome, driving the demand for treatment options. According to the American Academy of Ophthalmology, approximately 16 million people in the U.S. have been diagnosed with dry eye disease. This large patient population supports the region's dominance in the market for dry eye treatments.

North America benefits from strong research and development activities in the healthcare sector. This leads to innovative product launches and advanced treatment options for dry eye syndrome. The region's robust healthcare infrastructure and high awareness of eye health among the population further cement its market dominance.

Furthermore, the increasing use of digital devices and screen time, particularly in the U.S., has contributed to a rising number of dry eye cases. A report from the Vision Council revealed that nearly 80% of American adults use digital devices for more than two hours per day, which significantly increases the risk of developing dry eye. This growing trend is fueling the demand for effective treatments in North America.

How Do Demographic Shifts Shape the Market Landscape in the Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth rate within the Dry Eye Syndrome Treatment Market during the forecast period. The rapid urbanization and increasing pollution levels in Asia-Pacific are contributing to the rising prevalence of dry eye syndrome. A study published by the World Health Organization (WHO) highlighted that many major cities in Asia, such as New Delhi and Beijing, experience high levels of air pollution, which exacerbates eye health issues, including dry eye.

The aging population across many countries in the Asia-Pacific region is another significant driver for the Dry Eye Syndrome Treatment Market. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the number of people aged 60 or older in Asia-Pacific is expected to increase from 630 million in 2020 to 1.3 billion by 2050. As dry eye syndrome is more prevalent among older adults, this demographic shift is contributing to the growing demand for treatment solutions.

Furthermore, the rapid adoption of digital devices, particularly in countries like China, Japan, and India, is fueling the rise in dry eye syndrome cases. According to a report by the Indian Council of Medical Research (ICMR), more than 50% of Indian adults experience digital eye strain due to excessive screen time, leading to a higher prevalence of dry eye symptoms. This growing trend of digital device usage is significantly boosting the demand for dry eye treatments in the Asia-Pacific region.

Competitive Landscape

The Dry Eye Syndrome Treatment Market's competitive landscape is characterized by a diverse range of companies, including pharmaceutical giants, specialty eye care companies, and innovative startups, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the Dry Eye Syndrome Treatment Market include:

Novartis AG, Allergan plc, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Akorn, Inc., Thea Pharmaceuticals Limited, OASIS Medical.

Latest Developments

In May 2023, Bausch + Lomb acquired Blink Tears from Johnson & Johnson Vision. This acquisition strengthens Bausch + Lomb's over-the-counter eye care product portfolio, expanding its market reach in the dry eye treatment space.

In October 2022, Novartis received FDA approval for its Xiidra (lifitegrast ophthalmic solution) for the treatment of dry eye disease in patients 17 years and older. The approval enhances the company's stronghold in the growing dry eye market by offering a proven therapeutic solution.

Dry Eye Syndrome Treatment Market, By Category

• Product Type:
• Artificial Tears
• Anti-inflammatory Drugs
• Punctal Plugs
• Secretagogues
• Others
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Rest of the World

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DRY EYE SYNDROME TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DRY EYE SYNDROME TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Artificial Tears
• 5.3 Anti-inflammatory Drugs
• 5.4 Punctal Plugs
• 5.5 Secretagogues
• 5.6 Others

6 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL DRY EYE SYNDROME TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Novartis AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Allergan plc
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Bausch Health Companies Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Santen Pharmaceutical Co., Ltd.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Johnson & Johnson
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Otsuka Pharmaceutical Co., Ltd.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sun Pharmaceutical Industries Ltd.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Akorn, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Thea Pharmaceuticals Limited
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 OASIS Medical
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research